To assess the efficacy of esomeprazole 40 mg once daily in subjects who still had heartburn after receiving rabeprazole

Study identifier:D961HL00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An 8-week, open label, multicentre study to assess the efficacy of esomeprazole 40 mg once daily in subjects with continuing symptoms of heartburn following treatment with a previous rabeprazole.

Medical condition

Heartburn

Phase

Phase 4

Healthy volunteers

No

Study drug

esomeprazole 40 mg

Sex

All

Actual Enrollment

101

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Jun 2011
Study Completion Date: 01 Jun 2011

Study design

Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Quintiles East Asia Pte. Ltd.

Inclusion and exclusion criteria